Research Publications

The influence of peripheral arterial disease on outcomes: a pooled analysis of mortality in eight large randomized percutaneous coronary intervention trials.

Saw J, Bhatt DL, Moliterno DJ, Brener SJ, Steinhubl SR, Lincoff AM, Tcheng JE, Harrington RA, Simoons M, Hu T, Sheikh MA, Kereiakes DJ, Topol EJ

Genetic susceptibility to myocardial infarction and coronary artery disease.

Topol EJ, Smith J, Plow EF, Wang QK

The genetics of health.

Nadeau JH, Topol EJ

Identification of atherosclerosis-modifying genes: pathogenic insights and therapeutic potential.

Smith JD, Topol EJ

Direct thrombin inhibition appears to be a safe and effective anticoagulant for percutaneous bypass graft interventions.

Kao J, Lincoff AM, Topol EJ, Madrid A, J Price M, Sawhney N, Teirstein PS

The prognostic value of the admission and predischarge electrocardiogram in acute coronary syndromes: the GUSTO-IIb ECG Core Laboratory experience.

Goodman SG, Fu Y, Langer A, Barr A, Tan M, Wagner GS, Barbagelata A, Sgarbossa EB, Birnbaum Y, Granger CB, Califf RM, Van de Werf F, Topol EJ, Armstrong PW, GUSTO-IIb Investigators

Meta-analysis: cardiovascular events associated with nonsteroidal anti-inflammatory drugs.

Salpeter SR, Gregor P, Ormiston TM, Whitlock R, Raina P, Thabane L, Topol EJ

Gene variants of VAMP8 and HNRPUL1 are associated with early-onset myocardial infarction.

Shiffman D, Rowland CM, Louie JZ, Luke MM, Bare LA, Bolonick JI, Young BA, Catanese JJ, Stiggins CF, Pullinger CR, Topol EJ, Malloy MJ, Kane JP, Ellis SG, Devlin JJ

Integrative medicine: implementation and evaluation of a professional development program using experiential learning and conceptual change teaching approaches.

Hewson MG, Copeland HL, Mascha E, Arrigain S, Topol E, Fox JE

Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: predictors and outcome in the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial.

Exaire JE, Butman SM, Ebrahimi R, Kleiman NS, Harrington RA, Schweiger MJ, Bittl JA, Wolski K, Topol EJ, Lincoff AM, REPLACE-2 Investigators